Mesa Laboratories Financial Results
Mesa Laboratories reported second quarter fiscal 2027 results with revenues increasing 2.6% to $62.3 million and net income rising 75.3% to $4.3 million. The company issued full-year fiscal 2027 guidance for the first time, forecasting revenues between $250 million and $255 million. Performance was driven by record revenues in the Sterilization and Disinfection Control division, partially offset by export-control delays in the Biopharmaceutical Development segment.
- Term
- Q2 2027
“Our second quarter showed the progress we are making and the work that remains. SDC is shipping more reliably on most of its product lines, and the Savings Plan we announced in October is under way. Today we are giving full-year guidance for the first time. We have built it conservatively, on a half-year of data under the changes we have made, because a number that our shareholders can count on is worth more than one that flatters a quarter”
Dr. Siddhartha Kadia, President and CEO
“Second quarter revenues of $62,336 represented 2.6% organic (3.1% constant currency organic) growth, continuing positive organic growth in each quarter of FY27 to date. Growth was driven by SDC and CS, partially offset by BPD, which continued to be impacted by export-control processing delays, and CG. Adjusted EBITDA was 27.8% of revenues versus 23.5% in 2Q26. In the second quarter, we repaid $11,406 of debt and reduced our Total Net Leverage Ratio to 1.75”
John Sakys, Chief Financial Officer